News Release(2021)
2021
-
December 22, 2021
Submission of New Drug Application for Rovatirelin (KPS-0373) for the treatment of Spinocerebellar Degeneration
-
December 21, 2021
Positive Topline Results from Japan Phase III Clinical Study (Period 1) of Fostamatinib for Chronic Immune Thrombocytopenic Purpura
-
November 15, 2021
Change of Marketing Scheme for "RECTABUL®2mg Rectal Foam 14 Doses" and AJM300 (Nonproprietary Name: Carotegrast Methyl), Both for Treatment of Ulcerative Colitis - Agreement Concluded
-
September 27, 2021
Marketing Authorization Approval in Japan for TAVNEOS® Capsules 10mg, a selective Complement C5a Receptor Antagonist
-
September 15, 2021
New Drug Application submitted to U.S. FDA for Linzagolix for the treatment of uterine fibroids
-
September 2, 2021
Licensing Agreement for GnRH Antagonist Linzagolix with Bio Genuine in China
-
August 19, 2021
Launch of UPASITA® IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
-
August 5, 2021
Sub-licensing Agreement for Spleen Tyrosine Kinase Inhibitor Fostamatinib with Inmagene Biopharmaceuticals
-
July 1, 2021
Phase III Clinical Study Data of AJM300 (Nonproprietary Name: Carotegrast Methyl) Conducted in Japan for Treatment of Ulcerative Colitis (AJM300/CT3 Study) will be presented in the 16th Congress of European Crohn's and Colitis Organisation (ECCO'21)
-
June 28, 2021
Sub-licensing Agreement for Spleen Tyrosine Kinase Inhibitor "Fostamatinib (R788)" with JW Pharmaceutical Corporation
-
June 23, 2021
Announcement of Marketing Authorization Approval in Japan and Co-promotion Agreement of UPASITA® IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
-
May 28, 2021
EA Pharma Filed Marketing Approval Application for AJM300 (Nonproprietary Name: Carotegrast Methyl) Indicated for Treatment of Ulcerative Colitis
-
March 24, 2021
Participation in global Phase III clinical trial for CG0070, a drug for bladder cancer
-
March 1, 2021
Submission of New Drug Application for Avacopan (CCX168), a Complement C5a Receptor Inhibitor, in Japan
-
January 13, 2021
Results of Phase III Clinical Study of AJM300 (Nonproprietary Name: Carotegrast Methyl) for Treatment of Ulcerative Colitis Conducted in Japan (AJM300/CT3 Study) - Primary Endpoint Achieved -